about
Systematic review on irrational use of medicines in China and VietnamContract Research Organizations (CROs) in China: integrating Chinese research and development capabilities for global drug innovation.Effects of the expansion of doctors' offices adjacent to private pharmacies in Mexico: secondary data analysis of a national survey.Comparing public and private hospitals in China: evidence from GuangdongAvailability and use of essential medicines in China: manufacturing, supply, and prescribing in Shandong and Gansu provinces.Evaluation of the effects of comprehensive reform on primary healthcare institutions in Anhui ProvinceHealthcare reform in the United States and China: pharmaceutical market implicationsThe political economy of healthcare reform in China: negotiating public and private.National Essential Medicines List and policy practice: a case study of China's health care reformThe effect of the National Essential Medicines Policy on health expenditures and service delivery in Chinese township health centres: evidence from a longitudinal study.Measuring access to medicines: a survey of prices, availability and affordability in Shaanxi province of China.A price and use comparison of generic versus originator cardiovascular medicines: a hospital study in Chongqing, China.Prescribing efficiency of proton pump inhibitors in China: influence and future directionsUptake of new antidiabetic medications in three emerging markets: a comparison between Brazil, China and Thailand.Overuse of antibiotics for the common cold - attitudes and behaviors among doctors in rural areas of Shandong Province, ChinaShort-term differences in drug prices after implementation of the national essential medicines system: A case study in rural Jiangxi Province, China.Addressing Antibiotic Abuse in China: An Experimental Audit Study.Impact of anticancer drugs price cut on physician's prescription choices on first-line chemotherapy regimens and health expenditure for advanced non-small cell lung cancer in ChinaDrug Brand Response and Its Impact on Compliance and Efficacy in Depression Patients.An analysis of China's national essential medicines policy.Community pharmacy practice in China: past, present and future.Priority setting for health in emerging markets.Policy options for pharmaceutical pricing and purchasing: issues for low- and middle-income countries.Review of ongoing initiatives to improve prescribing efficiency in China; angiotensin receptor blockers as a case history.Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review.Availability, Price, and Affordability of Selected Essential Medicines for Chronic Diseases in 11 Countries of the Asia Pacific Region: A Secondary Analysis.Analysis of the influence of recent reforms in China: cardiovascular and cerebrovascular medicines as a case history to provide future direction.The cyclical behaviour of public and private health expenditure in China.Governance structure reform and antibiotics prescription in community health centres in Shenzhen, China.Time trends and determinants of pharmaceutical expenditure in China (1990-2009).Distribution of essential medicines to primary care institutions in Hubei of China: effects of centralized procurement arrangements.Pharmaceutical pricing: an empirical study of market competition in Chinese hospitals.Effects on the medical revenue of comprehensive pricing reform in Chinese urban public hospitals after removing drug markups: case of Nanjing.Clinical trial design and recommendations: collectively, we can take them.Prices, availability and affordability of essential medicines in rural areas of Hubei Province, China.Access to medicines for acute illness and antibiotic use in residents: A medicines household survey in Sichuan Province, western China
P2860
Q28544792-FF0C9974-40A1-4B90-A490-D6C168912A36Q30390211-93644072-5DC1-4E0F-AD81-6DF574729380Q30825750-C3B3870F-1E27-453F-8600-678DCC7C4E27Q33544912-F5C81F5B-E3C8-44BD-AF9B-32C27AA64AA0Q33634671-7ACA7931-C026-4CB1-BEC6-3D6A73E34B16Q33927619-C551C93A-4502-47F1-9EC7-8490EF24F0EDQ33984685-7A54350A-C0CC-4FDA-850C-89C5C6DB5CABQ34372441-893C156A-5E5A-4EA1-A93F-40C53BA1949CQ34476482-997E44BB-CA64-4A28-8EB9-D342D16F670DQ34767907-6604BA66-A43F-4B54-B39C-8D3D286CF033Q34926238-9E08DD03-C211-48CE-8274-EE1283648ECDQ35007915-0A647D17-7DF5-4449-A6A5-BCF8290CFCA9Q35021173-5E91ED4D-BAF9-4B61-992B-5B62A4AA6928Q35128657-36E25666-C079-49A6-BEC3-9A1201C0B6C7Q35321313-215980AB-6924-4CE0-9259-8161121452D2Q36210112-06D09003-C48E-47BE-9823-04ED051C70A6Q36645966-F257E520-AB1B-4E7E-B561-3D1EFEA0A7ACQ37411137-53BAD31E-A379-4963-8207-8466C60A6984Q37574860-AB8492B3-B80C-4A72-87F5-7AB600555A96Q37879913-EC97E518-F43A-45E9-B8FA-C4035C67F6F1Q38105486-A0FC03F3-AA5F-48FE-B08A-E16AEF362B4EQ38162887-11111D3D-4F5C-4761-86F0-AAF85273FF04Q38178581-97CCCA0A-C73F-4FBB-8306-54A8ECD2C88CQ38263092-8B3EE00B-26C8-4492-ACBF-6EB8278F2833Q38517704-AEC6D5CD-7F49-4062-87C6-35C18D46474DQ38843019-25B593BC-6246-4B26-AA10-8EA06B8047D0Q39120116-0A029903-A972-4ECF-AE20-D1838C251053Q40122928-CD2AB692-D2C9-4FC2-9CD4-235B78F652FFQ43644546-099E99AC-47E3-4E7F-BBBE-810A06A1C177Q43759370-6E747B74-5B28-45D7-BEB4-A559C8B7FF28Q44073239-56289F4B-E033-4CD2-B6A0-F50CDF1E1FDFQ45805889-6C3C432E-6BE3-4FB2-BDB3-698DFA4661C3Q47594303-0CFC7E22-81C8-4C5F-B80B-D3E5B2038524Q47898180-7B15EDCF-DA81-485D-987F-9EDD05DEB259Q50159168-4565EA76-CC8B-433C-8EA8-ED07CF9E3716Q58775262-5762A9C8-634F-494E-B171-D4F12E8BD2AE
P2860
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
Pharmaceutical policy in China.
@en
type
label
Pharmaceutical policy in China.
@en
prefLabel
Pharmaceutical policy in China.
@en
P2093
P1433
P1476
Pharmaceutical policy in China.
@en
P2093
Caitlin Liu
Karen Eggleston
Michael A Santoro
Qingyue Meng
P304
P356
10.1377/HLTHAFF.27.4.1042
P407
P577
2008-07-01T00:00:00Z